KANT (Kineta) Tax Rate % : 0.00% (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Kineta Tax Rate %?

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Kineta's Tax Expense for the three months ended in Jun. 2024 was $0.00 Mil. Kineta's Pre-Tax Income for the three months ended in Jun. 2024 was $-2.61 Mil. Therefore, Kineta's Tax Rate % for the quarter that ended in Jun. 2024 was 0.00%.

Kineta Tax Rate % Historical Data

The historical data trend for Kineta's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kineta Tax Rate % Chart

Kineta Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Tax Rate %

Kineta Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Tax Rate %	Get a 7-Day Free Trial								-	-	-	-	-

Kineta Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Kineta's Tax Rate % for the fiscal year that ended in Dec. 2023 is calculated as

Tax Rate %	=	Tax Expense (A: Dec. 2023 )	/	Pre-Tax Income (A: Dec. 2023 )
	=	0	/	-14.076
	=	0.00 %

Kineta's Tax Rate % for the quarter that ended in Jun. 2024 is calculated as

Tax Rate %	=	Tax Expense (Q: Jun. 2024 )	/	Pre-Tax Income (Q: Jun. 2024 )
	=	0	/	-2.605
	=	0.00 %

Kineta Tax Rate % Related Terms

Thank you for viewing the detailed overview of Kineta's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kineta Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kineta Inc (OTCPK:KANT) » Definitions » Tax Rate %

Comparable Companies

Traded in Other Exchanges

N/A

Address

7683 SE 27th Street, Suite 481, Mercer Island, WA, USA, 98040

Website

https://www.kinetabio.com

Kineta Inc is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. The company's asset is KVA12.1, a VISTA blocking immunotherapy.

Executives

Raymond J. Bartoszek	director	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Shawn Iadonato	director, officer: Chief Executive Officer	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Craig W. Philips	officer: President	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Pauline Kenny	officer: General Counsel	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Keith Baker	officer: Chief Financial Officer	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Thierry Guillaudeux	officer: Chief Scientific Officer	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Scott J. Dylla	director	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Marion R Foote	director	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Michael D Wyzga	officer: See Remarks	C/O YUMANITY, INC., 40 GUEST STREET, SUITE 4410, BOSTON MA 02135
Devin Whittemore Smith	officer: SVP and General Counsel	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Kimberlee C Drapkin	director	PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ajay Verma	officer: EVP, Head of R&D	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Lynne Zydowsky	director	C/O YUMANITY THERAPEUTICS, INC., 40 GUEST STREET, BOSTON MA 02135
Susan L. Lindquist Exempt Marital Trust	10 percent owner	C/O NANCY E. DEMPZE, HEMENWAY & BARNES, LLP, 75 STATE STREET, BOSTON MA 02109
Susan L. Lindquist Massachusetts Non-exempt Marital Trust	10 percent owner	C/O NANCY DEMPZE, HEMENWAY & BARNES, LLP, 75 STATE STREET, BOSTON MA 02109